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Background:Melioidosis is difﬁcult to diagnose clinically and culture of Burkholderia pseudomallei is the current,
imperfect gold standard. However, a reliable point-of-care test (POCT) could enable earlier treatment and
improve outcomes.
Methods: We evaluated the sensitivity and speciﬁcity of the Active Melioidosis DetectTM (AMD) rapid test as a
POCT and determined how much it reduced the time to diagnosis compared with culture.
Results: We tested 106 whole blood, plasma and buffy coat samples, 96 urine, 28 sputum and 20 pus
samples from 112 patients, of whom 26 (23.2%) were culture-positive for B. pseudomallei. AMD sensitivity and
speciﬁcity were 65.4 and 87.2%, respectively, the latter related to 10 weak positive reactions on urine samples,
considered likely false positives. The positive predictive value was 60.7%, negative predictive value was 89.3%
and concordance rate between operators reading the test was 95.7%; time to diagnosis decreased by a median
of 23 h.
Conclusions: Our ﬁndings conﬁrm that a strongly positive AMD result can reduce the time to diagnosis of
melioidosis. However, the AMD currently has a disappointing overall sensitivity, especially with blood fractions,
and speciﬁcity problems when testing urine samples.
Keywords: Burkholderia pseudomallei, immunoassay, Laos, melioidosis, point-of-care technology
Introduction
Melioidosis is an infectious disease caused by Burkholderia pseu-
domallei, a gram-negative, oxidase-positive, saprophytic environ-
mental bacillus.1 The infection is highly endemic in South-East
Asia and northern Australia,2 but is also widely underreported.3
The incidence is highest during the rainy season (May–October in
South-East Asia), especially following severe weather events.4–6
The mortality rate ranges from 20 to 50%, rendering melioidosis
a common cause of death in some areas.7 In low-resource set-
tings, the wide differential diagnosis can prove problematic for
physicians, and has led to the nickname ‘the great mimicker’.8
Currently, the gold standard for diagnosis is culture, using
selective media such as Ashdown’s agar and selective broth for
sites with a normal ﬂora. However, in settings such as Laos, these
are rarely available.9 Furthermore, the bacterium can be easily
misidentiﬁed.9 Moreover, the culture methods currently used
have a sensitivity thatmay be as low as 60.2%,10 and take several
days before the diagnosis is conﬁrmed,11 leading to potentially
fatal delays before the patient receives appropriate treatment.12
New tools are therefore needed to diagnose the disease rapidly
and accurately. Recently, a qualitative, membrane-based lateral
ﬂow immunoassay point-of-care test (POCT) that detects the
capsular polysaccharide of B. pseudomallei, the ActiveMelioidosis
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DetectTM (AMD), has been developed by InBios (Seattle, WA,
USA).13 The AMD has undergone a small number of evaluations
for the direct detection of B. pseudomallei in a range of clinical
samples12–17 as well as for the detection of the organism in
blood culture broths.15,18 Such a test, which is easy to use and
relatively cheap, could prove a very valuable tool in resource-
limited settings.
In this study, we aimed to evaluate the AMD as a POCT for
suspected melioidosis, testing all available samples in real time
as soon as possible after the admission of the patient, to compare
its sensitivity, speciﬁcity and time to presumptive diagnosis with
that of culture.
Methods
Study site and population
The study was carried out in Mahosot Hospital, Vientiane, Lao
People’s Democratic Republic. The hospital serves patients from
Vientiane and is also amain national referral hospital for patients
from other provinces. The number of patients with melioidosis
diagnosed in the hospital has been steadily increasing in recent
years.19 Since melioidosis is highly protean in its manifestations,
study entrywas simply basedona clinical suspicion ofmelioidosis
by the responsible local physician. Patientswere actively recruited
by one of the investigators (MCR) visiting the Adult and Pediatric
Infectious Diseases, Ear-Nose-Throat, General Medicine, Adult
Intensive Care Unit, Pulmonary and Gastroenterology/Hematol-
ogywards at Mahosot Hospital at least once a day. The studywas
conducted throughout the rainy season (from June to October)
in 2017.
Patient enrolment and sampling
All patients with clinically suspectedmelioidosis were considered
for inclusion. The patient or a legal representative was asked
to provide written informed consent before being enrolled. A
standard set of samples was obtained as soon as possible after
melioidosis was suspected by the local physician. This included
blood cultures, EDTA blood, throat swab, urine, sputum, pus
and body ﬂuids (e.g. pleural or joint effusion) when clinically
indicated and feasible. All patients from whom B. pseudomallei
was isolated were started on the standard regimen20 for the
treatment of melioidosis as soon as possible after the laboratory
informed the responsible clinician of the suspected diagnosis.
When an AMD was positive, the result was communicated by a
member of the laboratory clinical team to the physician caring
for the patient, explaining that the test was under evaluation,
and a decision wasmade about the need for treatment based on
the test result in the context of the clinical and epidemiological
features. Treatment and outcome of each case were recorded on
a standard proforma.
Laboratory procedures
All samples obtained were tested as soon as possible after their
receipt in the laboratory. The AMDs were performed according
to themanufacturer’s instructions (see the Supplementary Data)
for all samples except blood. For these, an aliquot of the EDTA
blood sample was taken and the remaining EDTA blood was
separated into plasma and buffy coat fractions by centrifugation
(2060 rpm for 8 min). Next, 35 μl of each fraction was added to
one drop of lysis buffer and then 35 μl of the mixture was added
to three drops of chase buffer, mixed with a pipette and tested.
The results were read independently after 15 min by two
different operators, one of whomwas blind to clinical details. Line
intensity was deﬁned as ‘strong’ if the line was clearly visible to
the naked eye and in a photograph, and ‘weak’ if the line was
hard to see with the naked eye and/or in a photograph. When
discordant results were obtained, the AMD strips were reviewed
by a third person who decided the line intensity. Weak lines were
considered positive only if both investigators agreed that they
were positive.
Blood cultureswere processed as described:21 the bottleswere
incubated in air at 37◦C for 7 d, examined daily and, if turbid, were
subcultured onto blood agar, plus chocolate and MacConkey
agar if gram-negative rods were observed on the gram stain of
the broth. Pus and sputum samples were cultured directly on
non-selective media, Ashdown agar and in enrichment broths
as described.11 Centrifuged deposits of urine were cultured on
Ashdown agar. Any gram-negative, oxidase-positive rods and all
blood culture broths containing gram-negative rods were tested
with a latex agglutination reagent speciﬁc for the extracellular
polysaccharide of B. pseudomallei.22 Conﬁrmation of identity of
latex-positive colonies was performed by testing with API20NE
(bioMérieux, Basingstoke, UK). The time between the receipt of
samples until the ﬁrst positive AMD result and the ﬁrst positive
latex agglutination test was recorded.
Statistical analysis
We predicted the recruitment of 40 patients based on data from
previous rainy seasons. Assuming a sensitivity of the AMD of
75%, the precision of the sensitivity with this sample size was
estimated as being between 59 and 87% (95% CIs), which would
be similar to or higher than the reported sensitivity of culture
(60.2%).10 Data analysis was performed with STATA statistical
package release 14.0 (Stata Corporation, College Station, TX,
USA) and MedCalc (https://www.medcalc.org/calc/diagnostic_te
st.php; Ostend, Belgium). We performed a Shapiro-Wilk analysis
to test the normal distribution of quantitative variables. When
quantitative variables were normally distributed, the results were
expressed as the mean with 95% CIs, otherwise median and IQR
(25th–75th percentile) were reported. Qualitative variables were
summarized as counts and percentages to calculate sensitivi-
ties, speciﬁcities, the positive predictive value (PPV), the negative
predictive value (NPV) and the estimated 95% CIs. Results were
initially analyzed by patient according to whether or not they had
any positive culture for B. pseudomallei. Concordance between
the AMD and culture were evaluated with Cohen’s kappa; the
kappa-statistic measure of agreement varies from 0 (no match)
to 100 (perfect match). Analysis was also performed by speci-
men type: AMD results on blood fractions were compared with
concurrently taken blood cultures, otherwise AMDwas compared
with culture results on the same specimen. The Landis and Koch
criteria23 were used to categorize agreement between the two
operators as follows: 0: poor; 0–20: slight; 21–40: fair; 41–60:
moderate; 61–80: substantial; 81–100: almost perfect. To assess
2
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Table 1. Demographic features and locations of patients
Class All patients recruited (n=112) Burkholderia pseudomallei
culture-positive patients (n=26)
Burkholderia pseudomallei
AMD-positive patients (n=28)
Age, y
<15 11(9.8%) 5 (19.3%) 4 (14.3%)
15–39 22(19.6%) 5 (19.3%) 5 (17.9%)
40–60 51(55.5%) 11 (42.3%) 12 (42.9%)
>60 28(25%) 5 (19.3%) 7 (25%)
Gender
Female 59(52.7%) 12 (46.1%) 11 (39.3%)
Male 53(47.3%) 14 (53.8%) 17 (60.7%)
Ward of recruitment
General Medicine 25(22.3%) 1 (3.8%) 5 (17.9%)
Pulmonary 20(19.6%) 5 (19.3%) 6 (21.4%)
Adult Intensive Care Unit 18(16.1%) 6 (23.1%) 3 (10.7%)
Ear-Nose-Throat 16(14.3%) 5 (19.3%) 4 (14.3%)
Adult Infectious Diseases 15(13.4%) 6 (23.1%) 6 (21.4%)
Gastroenterology and Hematology 8 (7.1%) 0 1 (3.6%)
Pediatric Infectious Diseases 7 (6.2%) 1 (3.8%) 1 (3.6%)
Surgery 2 (1.8%) 2 (7.7%) 2 (7.1%)
International Clinic 1 (0.9%) 0 0
statistical signiﬁcance of the difference between time to diagno-
sis with AMD and culture, we used aWilcoxon signed-rank test. A
p-value of <0.05 was considered signiﬁcant.
Results
Patients and samples
We enrolled 112 patients with suspected melioidosis during the
study period, of whom 59 were female (52.7%). Twenty-six
patients (23%), including 12 females (46.2%), proved to have
culture-positive melioidosis. From the 112 patients, we collected:
106 whole blood plasma and buffy coat samples, all of which
had concurrent blood cultures; 96 urine samples (including 86
midstream and 10 catheter urine samples); 28 sputum samples
and 20 pus samples. In addition, 107 throat swabs from these
patients were cultured for B. pseudomallei, which is part of the
normal local diagnostic work-up for patients with suspected
melioidosis.24 Throat swabs and blood cultureswere not available
for ﬁve and six patients, respectively, as these samples were not
requested by the physician responsible. Details of the patients
and their ward locations are shown in Table 1.
Of the 26 patients with culture-positive melioidosis, 22
(84.2%) received speciﬁc treatment for melioidosis during
hospital admission. Among the latter, 18 survived (81.8%)
and four died (18.2%). Three of the 26 culture-positive cases
(12%) did not receive speciﬁc treatment for melioidosis (one
refused treatment and two died before they could be treated)
and one (3.8%), who had originally been admitted to Mahosot
Hospital, was subsequently transferred and treated elsewhere
and information about their management and outcome was not
available.
Analysis by patient
In total, 26 patients had melioidosis conﬁrmed by culture, of
whom 17 (65.4%) had positive AMD results from at least one
sample. Of the 86 patients with negative culture, 75 (87.2%)
were negative by AMD on all available samples. The AMD thus
showeda sensitivity of 65.4% (95%CI 44.3 to 82.8%), a speciﬁcity
of 87.2% (95% CI 78.3 to 93.4%), a PPV of 60.7% (95% CI
45.4 to 74.2%) and a NPV of 89.3% (95% CI 83 to 93.4%) for
the detection of culture-positive melioidosis in the ‘by patient’
analysis. The concordance rate between AMD and culture was
54.3% (95% CI 36.2 to 72.3%).
Analysis by sample type
The agreement between the two operators reading the AMD
results was 95.7% (95% CI 90.8 to 100%), corresponding to an
almost perfect match following Landis and Koch criteria.23 The
results were analyzed by sample type, using culture as the gold
standard, as shown in Table 2. Sensitivities ranged from 0% (95%
CI 0 to 26.5%) for buffy coat to 85.7% (95% CI 42.1 to 99.6%)
for pus. Speciﬁcities ranged from 79.6% (95% CI 70 to 87.2%)
for urine to 100% for whole blood, buffy coat, sputum and pus.
PPVs ranged from 9.5% (95% CI 4.1 to 20.5%) for urine to 100%
for whole blood, sputum and pus, and NPVs ranged from 88.7%
(95% CI 88.7 to 88.9%) for buffy coat to 98.7% (95% CI 93.7 to
99.7%) for urine.
3
D
ow
nloaded from
 https://academ
ic.oup.com
/trstm
h/advance-article-abstract/doi/10.1093/trstm
h/trz092/5602277 by guest on 23 O
ctober 2019
M. C. Rizzi et al.
Ta
bl
e
2.
Cu
ltu
re
-A
ct
iv
e
M
el
io
id
os
is
De
te
ct
TM
(A
M
D)
co
m
pa
ris
on
by
sa
m
pl
e
ty
pe
Sa
m
pl
e
ty
pe
N
o.
Cu
ltu
re
-
po
si
tiv
e
AM
D-
po
si
tiv
e
Po
ss
ib
le
AM
D
‘fa
ls
e
po
si
tiv
es
’
Se
ns
iti
vi
ty
(%
)(
95
%
CI
)
Sp
ec
iﬁ
ci
ty
(%
)(
95
%
CI
)
PP
V
(%
)(
95
%
CI
)
N
PV
(%
)(
95
%
CI
)
W
ho
le
bl
oo
d
10
6
12
a
2
0
16
.7
(2
.9
to
48
.4
)
10
0
(9
6.
2
to
10
0)
10
0
90
.4
(8
8
to
92
.4
)
Pl
as
m
a
10
6
12
a
4
1
25
(5
.5
to
57
.2
)
98
.9
(9
4.
2
to
10
0)
75
(2
5.
3
to
96
.4
)
91
.2
(8
8.
2
to
93
.5
)
Bu
ff
y
co
at
10
6
12
a
0
0
0
(0
to
26
.5
)
10
0
(9
6.
2
to
10
0)
-
88
.7
(8
8.
7
to
88
.9
)
U
rin
e
96
3
21
19
66
.7
(9
.4
to
99
.2
)
79
.6
(7
0
to
87
.2
)
9.
5
(4
.1
to
20
.5
)
98
.7
(9
3.
7
to
99
.7
)
Sp
ut
um
28
5
4
0
80
(2
8.
4
to
99
.5
)
10
0
(8
5.
2
to
10
0)
10
0
95
.8
(7
9.
9
to
99
.3
)
Pu
s
20
7
6
0
85
.7
(4
2.
1
to
99
.6
)
10
0
(7
5.
3
to
10
0)
10
0
92
.9
(6
7.
3
to
98
.7
)
a F
or
bl
oo
d
sa
m
pl
es
th
e
co
m
pa
ris
on
w
as
m
ad
e
be
tw
ee
n
th
e
ty
pe
of
sa
m
pl
e
lis
te
d
in
th
e
ta
bl
e
fo
rA
M
D
an
d
a
si
m
ul
ta
ne
ou
sl
y
co
lle
ct
ed
bl
oo
d
cu
ltu
re
.N
PV
,n
eg
at
iv
e
pr
ed
ic
tiv
e
va
lu
e;
PP
V,
po
si
tiv
e
pr
ed
ic
tiv
e
va
lu
e.
Positive urine results
Three patients had melioidosis conﬁrmed by urine culture. Of
these, two (66.7%) had a positive urine AMD result. Of the
93 patients with a negative urine culture, 19 (20%) had a
positive urine AMD result. However, nine (42.9%) of these
19 ‘false positives’ came from patients who grew B. pseudomallei
from other samples (including throat swabs) and were thus
possibly detecting genuine antigenuria, whereas 10 (47.6%)were
culture-negative on all samples obtained, resulting in an overall
sensitivity for a positive urine AMD in detecting culture-positive
melioidosis of 66.7% (95% CI 9.4 to 99.2%) and a speciﬁcity of
79.6% (95% CI 70 to 87.2%). Of the nine positive AMDs from
patients with positive cultures at other sites, eight were read
as positive by both operators (three as strong lines and ﬁve as
weak lines), while one was read as positive only by the operator
totally blind to clinical details but was not conﬁrmed by the third
operator. The latter patient had a deep pus sample that was
positive by both culture and AMD. Of the other eight patients,
seven had positive cultures and/or AMD frommore than one site,
whereas one was culture-positive only from a throat swab.24
All 10 patients whose urine AMDs were positive but had no
evidence of culture-positive melioidosis gave only weak lines
in the AMD test. Eight of these were considered likely to be
genuinely false-positive reactions, as the clinical presentations
and courses of the patients were not consistent with melioidosis
since theywere discharged in good condition despite having been
treated with antibiotics that are not effective in melioidosis. The
interpretation in the other two patients is unclear: one started IV
ceftazidime butwas discharged for treatment elsewhere and one
was lost to follow-up, so their outcomes are unknown.
These results are summarized in Table 3.
Time to diagnosis
In 16 (61.5%) culture-positive patients, a positive AMD result was
available earlier than culture, but only in ﬁve did this actually
reduce the time until the patient received appropriate treatment,
as in six cases clinicians decided towait for culture results, in three
cases treatment for melioidosis had already been given on the
basis of clinical suspicion and in two cases nomelioidosis-speciﬁc
treatment was given because one patient died too early and the
other declined treatment. The time from sample collection to the
ﬁrst positive AMD result or presumptive positive culture result for
those patients positive in both tests was reduced by a median of
23.1 h by the AMD (IQR 6 h, p=0.003).
Discussion
Infection with B. pseudomallei is frequently severe, with septic
shock occurring in up to 21% of patients.25 The early administra-
tion of speciﬁc antibiotic treatment is key for securing a favorable
outcome. A simple, sensitive and speciﬁc rapid diagnostic test
that can be performed directly on clinical samples would be
highly valuable, particularly as melioidosis is common in areas
where laboratory facilities and training are often scarce. Culture,
PCR and immunoﬂuorescence assays26,27 often cannot be rou-
tinely used in melioidosis-endemic areas because they require
dedicated facilities and highly trained staff. Tests for antibodies
4
D
ow
nloaded from
 https://academ
ic.oup.com
/trstm
h/advance-article-abstract/doi/10.1093/trstm
h/trz092/5602277 by guest on 23 O
ctober 2019
Transactions of the Royal Society of Tropical Medicine and Hygiene
Table 3. Urine active melioidosis detect (AMD) results in patients with culture-positive melioidosis in sites other than urine
Patient code AMD strength on urine Other positive AMD Burkholderia pseudomallei culture positive samples
011 Strong line - Blood culture, sputum
035 Weak line Sputum Throat swab, sputum
048 Weak linea Deep pus Deep pus (back abscess)
055 Weak line EDTA plasma Blood culture, throat swab
067 Weak line Throat swab sputum Blood culture
EDTA whole blood Throat swab
EDTA plasma Sputum
078 Strong line - Blood culture, pus swab (leg lesion)
086 Strong line Deep pus EDTA plasma Deep pus (spleen abscess)
092 Weak line EDTA whole blood Blood culture
EDTA plasma Pus swab (lumbar abscess)
105 Weak line - Throat swab
aThis result was read as positive by only one of the two operators and was not conﬁrmed by the third operator, so was read as negative.
to B. pseudomallei using techniques such as indirect haemag-
glutination, while widely used, are beset with problems of both
sensitivity and speciﬁcity,28 although assays using better charac-
terized antigens are being developed and showmore promise as
diagnostic tools.29 Latex agglutination is useful for rapid testing
of blood cultures growing gram-negative bacilli, but requires an
initial incubation step, which inevitably delays the time to positive
results.30 The clinical management of melioidosis could thus be
improved by a POC test. This study built on our previous evalua-
tion of the AMD,whichwas conducted at the same hospital,15 but
instead of using specimens passively received in the laboratory,
we actively encouraged the submission of all relevant specimens
(blood and urine, and sputum and pus whenever available) from
suspected melioidosis patients as soon as possible after hospital
admission. Using this approach we found that for patients with a
positive culture, the time to presumptive diagnosis was reduced
by a median of 23 h (p=0.003). In ﬁve cases, this actually led
to a reduction in the time between admission and the start
of treatment, and this might have happened in more patients
had the test been fully evaluated and licensed. However, two of
these ﬁve patients died, while three survived. Amuch larger study
would be needed to determine whether this test actually has
the potential to reduce mortality in patients with melioidosis. In
practical terms, the AMD is user-friendly as it requires little train-
ing and can give results in only 15 min. Moreover, in our hands
the inter-operator concordance was good. Although the test
is not yet available commercially, if marketed at relatively low
cost it could be suitable for resource-limitedmelioidosis-endemic
settings where culture facilities are frequently not available.
Nonetheless, there is clearly room for improvement, as our
‘by patient’ performance analysis of the AMD showed an over-
all disappointing sensitivity (65.4%) and speciﬁcity (87.2%) for
detecting culture-positive melioidosis. These are lower than the
85.7% sensitivity and 93.6% speciﬁcity by sample reported by
Shaw et al.14 The low AMD speciﬁcity in our study was almost
entirely due toweak positive reactions obtained on urine samples
and read as positive by at least one operator strictly following the
manufacturer’s instructions. On clinical grounds, we believe the
majority of these to be false positives, the cause of which requires
further investigation. Similar problems with urine samples were
also reported by Shaw et al.14 In our ‘by sample’ analysis, the
AMD performed directly on the various blood fractions had a
very low sensitivity compared with blood cultures (0% for buffy
coat, 16.7% for whole blood and 25% for plasma), as previ-
ously reported by Robertson et al.12 but so far not analyzed in
other studies. This presumably relates to low levels of circulating
antigen, even in patients with bacteremia and the compara-
tively large volumes of blood that are cultured. Sputum and pus
samples showed good sensitivities in our study (80 and 85.7%,
respectively), which were higher than the results obtained by
Woods et al. (sputum sensitivity 33.3%, pus 47.1%)15 and closer
to the sensitivity for pus samples found by Shaw et al. (93.1%).14
However, these two sample types were only available in 28
(25%) and 20 (22.4%) of the patients recruited, and seven (25%)
and ﬁve (25%) of the 26 culture-positive patients, respectively.
Thus, our results suggest that the collection of these samples in
patients suspected of having melioidosis is of great importance
wherever possible.
One possible explanation for false negative cultures is prior
antibiotic treatment, which is common in patients admitted to
hospital in Laos.31 Patients are routinely questioned about this
by medical staff although they are often unaware of the agents
they have taken or evenwhether thesewere antibiotics. However,
we feel that this is unlikely to have had a signiﬁcant impact
in our study as the oral agents readily available in Laos, such
as ampicillin and amoxicillin, have little or no activity against
B. pseudomallei, and even in hospitals the agentmost commonly
used for empirical treatment of sepsis, ceftriaxone, has low clini-
cal efﬁcacy in melioidosis.32
The polysaccharide antigen detected by the AMD has been
shown to be largely eliminated by renal ﬁltration in a murine
model, forming a single-walled nanotube structure that may
allow its ﬁltration through the glomerulus despite its high molec-
ular weight of 300 kDa.33 Thus, even when viable B. pseudomallei
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are not present in urine, antigenuria might result in a posi-
tive AMD. Urinary antigen detection appeared promising as a
diagnostic test for melioidosis in our previous evaluation of the
AMD15 with a sensitivity of 86.7% compared with culture.15 Urine
AMD had a lower sensitivity in the current evaluation (66.7%),
although again we found evidence of probable antigenuria in
nine patients who had a negative urine culture but a positive
culture from other sites. However, in this evaluation we found
problems with speciﬁcity of urine antigen detection. One possible
explanation for this is that the methodology for testing urine in
this study, as speciﬁed in the latest manufacturer’s instructions,
differed from that in our previous study, in which neat urine
was tested. This requires further evaluation. We believe that the
majority of these weak bands were likely to have been false pos-
itives as discussed above, but in future the use of an automated
reader to quantify line intensity or urine concentration may help
to distinguish between genuine antigenuria and false positive
reactions.
Conclusions
Our study has conﬁrmed the potential for a POC test to enable
earlier, potentially life-saving treatment in patients with melioi-
dosis. Sensitivity and speciﬁcity are good with pus and sputum if
these can be obtained, and a strong positive band on the AMD, as
currently formulated, is sufﬁcient evidence to start a patient on
treatment for melioidosis. Urine antigen detection is promising,
but further developments such as the modiﬁcation of the test
characteristics, implementation of an automated reader or the
use of urine concentrators may help to distinguish between true
and false positives. However, evaluations of the AMD undertaken
to date do not suggest that the AMD is likely to be useful for
testing blood samples. It should also be noted that, as with all
diagnostic tests, the sensitivity and speciﬁcity will never be 100%
and so some patients will need to be managed on the basis of a
strong clinical suspicion of melioidosis.
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